Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
Clinical trial NCT07106892 · RECRUITING
Trial details
- NCT number
- NCT07106892
- Sponsor
- Shanghai Henlius Biotech
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-15
- Primary completion
- 2026-12-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.